Recursion Pharmaceuticals Inc. (RXRX) Social Stream
RECURSION PHARMACEUTICALS INC (RXRX) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering RECURSION PHARMACEUTICALS INC.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-11 | 5 | $37 | $30 | $33.5 | $11.25 | 197.78% |
| 2021-12-07 | 5 | $37 | $30 | $33 | $11.25 | 193.33% |
| 2021-12-08 | 5 | $37 | $31 | $34.2 | $11.25 | 204% |
| 2022-01-14 | 5 | $37 | $28 | $32.8 | $11.25 | 191.56% |
| 2022-03-04 | 5 | $37 | $10 | $28.4 | $11.25 | 152.44% |
| 2022-05-10 | 4 | $37 | $10 | $22 | $11.25 | 95.56% |
| 2022-05-12 | 4 | $37 | $10 | $18.25 | $11.25 | 62.22% |
| 2022-05-18 | 5 | $37 | $9 | $18 | $11.25 | 60% |
| 2022-08-09 | 5 | $37 | $7 | $15.8 | $11.25 | 40.44% |
| 2022-08-13 | 5 | $37 | $8 | $16 | $11.25 | 42.22% |
| 2022-08-23 | 5 | $37 | $8 | $16.2 | $11.25 | 44% |
| 2022-09-10 | 6 | $37 | $8 | $16.2 | $11.25 | 44% |
| 2022-09-17 | 5 | $20 | $8 | $12.8 | $11.25 | 13.78% |
| 2022-11-08 | 5 | $20 | $8 | $13 | $11.25 | 15.56% |
| 2022-11-11 | 5 | $20 | $9 | $13.2 | $11.25 | 17.33% |
| 2023-02-08 | 5 | $20 | $8 | $13.2 | $11.25 | 17.33% |
| 2023-03-01 | 5 | $20 | $9 | $13.4 | $11.25 | 19.11% |
| 2023-03-06 | 5 | $20 | $9 | $13.6 | $11.25 | 20.89% |
| 2023-05-03 | 6 | $20 | $9 | $14.166 | $11.25 | 25.92% |
| 2023-05-09 | 6 | $17 | $9 | $12.833 | $11.25 | 14.07% |
| 2023-05-12 | 6 | $17 | $9 | $11.833 | $11.25 | 5.18% |
| 2023-06-06 | 7 | $17 | $8 | $11.285 | $11.25 | 0.31% |
| 2023-07-12 | 7 | $17 | $8 | $11.428 | $11.25 | 1.58% |
| 2023-08-29 | 8 | $33 | $9 | $14.875 | $11.25 | 32.22% |
| 2023-11-10 | 7 | $33 | $9 | $15.714 | $11.25 | 39.68% |
| 2023-12-19 | 7 | $33 | $9 | $15.285 | $11.25 | 35.87% |
The Trend in the Analyst Price Target
RXRX's average price target has moved up $1.12 over the prior 35 weeks.
RXRX reports an average of 86.22% for its upside potential over the past 47 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-01-23 | 5 | 20 | 8 | 13.200 | 8.71 | 51.55% |
| 2023-02-08 | 5 | 20 | 8 | 13.200 | 8.30 | 59.04% |
| 2023-03-06 | 5 | 20 | 9 | 13.600 | 8.21 | 65.65% |
| 2023-04-18 | 6 | 20 | 9 | 14.166 | 5.94 | 138.48% |
| 2023-07-12 | 7 | 17 | 8 | 11.428 | 12.08 | -5.4% |
RXRX Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 2.29 | 2 | 1 | 4 | 0 | 0 | 7 |
The Trend in the Broker Recommendations
Over the past 27 months, RXRX's average broker recommendation rating worsened by 0.49.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- RECURSION PHARMACEUTICALS INC's variance in analysts' estimates is lower than -2391.36% of all US stocks.
- RXRX has a greater average analyst price target than 671.81% of all US stocks.
- RXRX has a greater number of analysts covering the stock than 819.49% of stocks in the mid market cap category.
- In terms of how RECURSION PHARMACEUTICALS INC fares relative to Pharmaceutical Products stocks, note that its upside potential (average analyst target price relative to current price) is greater than 1025.61% of that group.
Stocks similar to RECURSION PHARMACEUTICALS INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are EXAI, SNDL, and ACB.
View All Top Stocks by Price Target
Make investment decisions regarding RXRX using the data that counts. Try POWR Ratings for free.